14 completed, 7 unknown, 3 recruiting, 3 terminated. 15 Phase 1, 12 Phase 2, 6 Not applicable, 2 Phase 3, 2 Phase 4.
Follow Corneal Neovascularization: new trials by email Literature Review of Corneal Neovascularization trials Research Report on Corneal Neovascularization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization Fine-needle diathermy, Bevacizumab - Corneal Neovascularisation | Not applicable | Recruiting | HoChiMinh City Eye Hospital | 51 | 2026-04-01 | 2026-06-11 |
| Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. Intrastromal anti-VEGF injection and topical antiviral eye drops, Conventional antiviral topical ocular drops. - Herpes Simplex Keratitis, Corneal Neovascularization | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2025-10-01 | 2026-01-09 |
| Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies Rare Diseases, Aniridia | Unknown | IRCCS Ospedale San Raffaele | 274 | 2024-05-01 | 2024-05-14 | |
| Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization. Corneal Neovascularization, Neutrophils | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 66 | 2023-01-01 | 2023-03-07 | |
| The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization KDR2-2 suspension eye drops - Corneal Neovascularization | Phase 1 / Phase 2 | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 60 | 2021-08-10 | 2021-08-18 |
| Corneal Crosslinking for Treatment of Corneal Neovascularization 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1% - Corneal Neovascularization | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 138 | 2021-05-03 | 2026-09-17 |
| Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment KDR2-2, Placebo - Corneal Neovascularization | Phase 1 | Unknown | Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd | 62 | 2020-08-26 | 2020-11-06 |
| An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Conbercept eye drop, Placebo - Corneal Neovascularization | Phase 1 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 39 | 2019-07-18 | 2020-01-02 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
| Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant - Limbal Stem Cell Deficiency | Phase 1 / Phase 2 | Completed | Massachusetts Eye and Ear Infirmary | 23 | 2016-08-01 | 2025-01-15 |
| Strategies for Management of Corneal Neovascularisation Fine Needle Diathermy, Bevacizumab - Corneal Neovascularisation | Phase 4 | Unknown | University of Nottingham | 40 | 2015-12-01 | 2015-12-02 |
| Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Gamunex-C - Corneal Neovascularization, Corneal Graft Failure | Phase 1 | Withdrawn | University of Utah | 2014-07-01 | 2016-08-05 | |
| A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel - Corneal Neovascularization, Corneal Graft Failure | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 75 | 2014-04-01 | 2020-08-10 |
| Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study Optical Coherence Tomography - Corneal Neovascularisation, Keratoconus | Phase 2 | Completed | Medical University of Vienna | 13 | 2014-03-14 | 2021-09-08 |
| Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Subconjunctival aflibercept, Placebo: Standard of care only - Corneal Neovascularization | Phase 1 | Terminated | Balamurali Ambati | 2 | 2013-06-01 | 2015-10-07 |
| Treatment of Corneal Neovascularization With Topical Pazopanib Pazopanib (5mg/ml) - Corneal Neovascularization | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 20 | 2010-11-01 | 2018-01-18 |
| Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel - Corneal Neovascularization, Corneal Graft Failure | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 30 | 2009-12-01 | 2018-06-15 |
| Bevacizumab for the Treatment of Corneal Neovascularization Bevacizumab - Corneal Neovascularization | Phase 2 | Unknown | Chang Gung Memorial Hospital | 10 | 2009-05-01 | 2009-10-15 |
| Topical IL-1-Ra for Treatment of Corneal Neovascularization Placebo, IL-1Ra - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Reza Dana, MD | 10 | 2009-04-01 | 2017-05-08 |
| Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Ranibizumab - Corneal Neovascularization | Phase 1 | Completed | University of Miami | 5 | 2008-10-01 | 2017-07-11 |
Showing 20 of 29. Sign in to see all of them.
Corneal Diseases (3) · Neovascularization, Pathologic (3) · Limbal Stem Cell Deficiency (2) · Rare Diseases (2) · Rosacea (2) · Aniridia (1) · Corneal Injuries (1) · Corneal Opacity (1) · Ectrodactyly-cleft lip-palate syndrome (1) · Eye Injuries (1) · Keratitis, Herpetic (1) · Keratoconus (1) · Lacerations (1) · Pemphigoid, Benign Mucous Membrane (1)
Eye Diseases (29) · Metaplasia (29) · Pathologic Processes (29) · Pathological Conditions, Signs and Symptoms (29) · Corneal Diseases (26) · Neovascularization, Pathologic (26) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Disease Attributes (2) · Wounds and Injuries (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Conjunctival Diseases (1) · Craniocerebral Trauma (1) · DNA Virus Infections (1)
Bevacizumab (11) · Carboxymethylcellulose Sodium (2) · Ranibizumab (2) · Sodium Chloride (2) · aflibercept (2) · Hizentra (1) · Immunoglobulins, Intravenous (1) · Interleukin 1 Receptor Antagonist Protein (1) · Laser Therapy (1) · Photochemotherapy (1) · Prednisolone (1) · Standard of Care (1) · Tomography, Optical Coherence (1) · Verteporfin (1) · pazopanib (1)
Reza Dana, MD (5) · Massachusetts Eye and Ear Infirmary (2) · Zhongshan Ophthalmic Center, Sun Yat-sen University (2) · Asociación para Evitar la Ceguera en México (1) · Balamurali Ambati (1) · Chang Gung Memorial Hospital (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Chonnam National University Hospital (1) · Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd (1) · HoChiMinh City Eye Hospital (1) · IRCCS Ospedale San Raffaele (1) · Instituto de Olhos de Goiania (1) · Medical College of Hampton Roads (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1)
United States (14) · China (4) · Taiwan (2) · Austria (1) · Israel (1) · Mexico (1) · South Korea (1) · Vietnam (1)
Reza Dana, MD, MPH, MSc (4) · Reza Dana, M.D., MPH (2) · Balamurali Ambati, M.D., Ph.D., M.B.A. (1) · Balamurali K Ambati, M.D., Ph.D., M.B.A. (1) · Belquiz A Nassaralla, PhD (1) · Ching-Hsi Hsiao, MD (1) · Francis W Price, Jr., MD (1) · Harminder S Dua, Professor (1) · Irit Bahar, MD (1) · John D. Sheppard (1) · Katarzyna Napora, MD, PhD (1) · Michael J Mines, MD (1) · Minh Nhat Le, Master of Ophthalmology (1)
PMID 19365012, PMID 19549103, PMID 19936307, PMID 20136420, PMID 22967868, PMID 23233252, PMID 26114826, PMID 27020759, PMID 27124775, PMID 40038272, PMID 40152603, PMID 40172865
2015 (1)